Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Donanemab (Primary) ; LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms TRAILBLAZER-ALZ
- Sponsors Eli Lilly
- 02 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2019 Planned End Date changed from 16 Sep 2021 to 12 Nov 2021.
- 02 Jul 2019 Planned primary completion date changed from 15 Oct 2020 to 11 Dec 2020.